Curated News
By: NewsRamp Editorial Staff
September 28, 2026
Novogenia AG Reports H1 2026 Results, Advances Personalized Health Growth
TLDR
- Novogenia AG's DNA and personalized health core grew amid a 7% revenue dip, positioning it for key launches and market expansion.
- Novogenia AG reported H1 2026 revenue of EUR 25.7 million and EBIT of EUR -4.7 million after cost cuts and strategic partnerships.
- Novogenia AG advances personalized prevention with new tests and Middle East launches, aiming to improve global healthcare through genetic insights.
- Novogenia AG, formerly Darwin AG, is building a 9,300-square-meter site in Hallwang and launching a Multi-Cancer Check.
Impact - Why it Matters
This news matters because Novogenia AG's performance and strategic initiatives provide insight into the evolving personalized healthcare and genetic testing market. Despite a revenue dip due to regulatory challenges in its trading segment, the company's core DNA analysis and personalized products business is growing, signaling robust demand for tailored health solutions. The significant cost reductions and improved operating profit demonstrate management's ability to navigate headwinds. Novogenia's international expansion efforts, particularly in the U.S. and Middle East, and its investment in a new state-of-the-art facility, position it to capitalize on the increasing consumer interest in preventive healthcare and genetic-based personalization. The rebranding to Novogenia AG reflects a unified strategy to enhance visibility and streamline communication. For investors and industry watchers, the upcoming conference participations offer opportunities to gauge the company's progress and potential. Ultimately, Novogenia's advancements could lead to more accessible and effective personalized health products, impacting how individuals manage their well-being through genetic insights.
Summary
Novogenia AG, an international healthcare company specializing in human genetics and personalized health products, has released its issuer report for the first half of 2026. The company, formerly known as Darwin AG, reported consolidated revenue of EUR 25.7 million, a 7% decline compared to the previous year, primarily due to lower volumes in its pharmaceutical and medical device trading segment caused by regulatory changes. However, the DNA analysis and personalized products segment achieved positive revenue growth, and cost-saving measures led to an operating profit improvement of approximately EUR 2.7 million. Despite this, EBIT remained negative at EUR -4.7 million, and consolidated net income fell to EUR -2.1 million from a positive EUR 2.0 million in the prior year, largely because the previous year benefited from a significantly higher financial result. As of June 30, 2026, the company held EUR 39.8 million in cash and cash equivalents, ensuring a solid financial position to drive future development.
CEO Dr. Daniel Wallerstorfer acknowledged that the first half did not meet expectations in all areas but highlighted encouraging year-on-year growth in the core DNA analysis and personalized health business, as well as a significant reduction in the cost base. He emphasized progress in new product development and strategic partnerships, which have set the stage for key product launches in the second half of the year. The company is also working to mitigate the impact of changes to digital platform algorithms on its sales channels. Notable strategic achievements include expanding the collaboration with 10X Health Systems, launching the enhanced Methylation Test MGT Plus in the U.S., advancing preparations with G42 in Abu Dhabi for a Middle East market launch, and introducing the Multi-Cancer Check. Additionally, Novogenia began construction of a new 9,300-square-meter facility in Hallwang near Salzburg, slated for completion in early 2028, and completed its rebranding from Darwin AG to Novogenia AG in July 2026.
To strengthen its international presence, Novogenia executives will participate in several upcoming conferences: the 5th Zurich Investor Day on September 29, 2026; the Abu Dhabi Future Health Summit from October 20–22, 2026; the ODDO BHF Autumn Round Table on October 22, 2026; and the Deutsches Eigenkapitalforum 2026 from November 23–25, 2026. These engagements will allow the company to engage with investors, analysts, and industry stakeholders. For more information, visit https://novogenia.com/novogenia-ag. The original release can be viewed on www.newmediawire.com.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Novogenia AG Reports H1 2026 Results, Advances Personalized Health Growth
